Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Evoke Pharma Company

EVOK
US30049G1040
A1W6DP

Price

5.34
Today +/-
+0.18
Today %
+3.75 %
P

Evoke Pharma stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Evoke Pharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Evoke Pharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Evoke Pharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Evoke Pharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Evoke Pharma Stock Price History

DateEvoke Pharma Price
10/17/20245.34 undefined
10/16/20245.14 undefined
10/15/20245.11 undefined
10/14/20245.09 undefined
10/11/20245.19 undefined
10/10/20245.32 undefined
10/9/20245.17 undefined
10/8/20245.57 undefined
10/7/20245.38 undefined
10/4/20245.25 undefined
10/3/20245.20 undefined
10/2/20244.95 undefined
10/1/20244.87 undefined
9/30/20244.76 undefined
9/27/20244.81 undefined
9/26/20245.08 undefined
9/25/20244.80 undefined
9/24/20245.00 undefined
9/23/20245.26 undefined
9/20/20244.51 undefined
9/19/20244.44 undefined

Evoke Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Evoke Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Evoke Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Evoke Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Evoke Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Evoke Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Evoke Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Evoke Pharma’s growth potential.

Evoke Pharma Revenue, EBIT and net profit per share

DateEvoke Pharma RevenueEvoke Pharma EBITEvoke Pharma Net Income
2026e32.67 M undefined11.56 M undefined1.38 M undefined
2025e20.4 M undefined1.55 M undefined178,704.01 undefined
2024e11.61 M undefined-4.3 M undefined-1.8 M undefined
20235.18 M undefined-7.43 M undefined-7.79 M undefined
20222.51 M undefined-7.79 M undefined-8.22 M undefined
20211.62 M undefined-8.15 M undefined-8.54 M undefined
202020,000 undefined-13.05 M undefined-13.15 M undefined
20190 undefined-7.15 M undefined-7.13 M undefined
20180 undefined-8.01 M undefined-7.57 M undefined
20170 undefined-11.23 M undefined-12.23 M undefined
20160 undefined-10.54 M undefined-10.75 M undefined
20150 undefined-11.82 M undefined-12.12 M undefined
20140 undefined-13.15 M undefined-13.25 M undefined
20130 undefined-2.6 M undefined-2.84 M undefined
20120 undefined-2 M undefined-2.02 M undefined
20110 undefined-2.41 M undefined-2.4 M undefined

Evoke Pharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (k)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e
0000000000125112032
-----------100.00150.00120.0081.8260.00
----------100.00100.0080.00---
0000000000124000
-2-2-2-13-11-10-11-8-7-13-8-7-7-4111
-----------800.00-350.00-140.00-36.365.0034.38
-2,000-2,000-2,000-13,000-12,000-10,000-12,000-7,000-7,000-13,000-8,000-8,000-7,000-1,00001,000
---550.00-7.69-16.6720.00-41.67-85.71-38.46--12.50-85.71--
0.090.090.20.50.540.781.241.381.862.122.683.140.28000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Evoke Pharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Evoke Pharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (k)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2011201220132014201520162017201820192020202120222023
                         
0.870.1224.214.168.699.017.685.325.668.079.149.844.74
00000000020300620673.07
0000000000000
000000000240190290481.84
0.0400.231.070.830.280.250.330.580.950.930.960.93
0.910.1224.4315.239.529.297.935.656.249.2810.5611.716.83
00000000140140101300
0000000000000
0000000000000
0000000000000
0000000000000
005601010101010101000241.64
00560101010101015015010130241.64
0.910.1224.9915.249.539.37.945.666.399.4310.5711.847.07
                         
18.2318.2300000000000
0.180.243.8745.1351.5262.673.282.6390.1195.67110.97119.73120.86
-17.84-19.86-22.69-35.94-48.06-58.81-71.04-78.6-85.73-98.89-107.42-115.65-123.44
0000000000000
0000000000000
0.57-1.4321.189.193.463.792.164.034.38-3.223.554.08-2.58
0.090.10.281.010.930.481.050.481.031.270.870.931.71
0.210.420.560.70.760.931.031.160.981.160.530.721.32
0.040.0600.01000005000
000000000100000
001.440.130.1500000000
0.340.582.281.851.841.412.081.642.017.531.41.653.04
00.981.514.24.2300005555
0000000000000
000.01004.13.7000.110.611.111.61
00.981.524.24.234.13.7005.115.616.116.61
0.341.563.86.056.075.515.781.642.0112.647.017.769.65
0.910.1324.9815.249.539.37.945.676.399.4210.5611.847.07
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Evoke Pharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Evoke Pharma's financial health and stability.

Assets

Evoke Pharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Evoke Pharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Evoke Pharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Evoke Pharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
-2-2-2-13-12-10-12-7-7-13-8-8-7
0000000000000
0000000000000
0000000004-501
0001112111111
0000000000000
0000000000000
-2-1-3-11-10-8-8-6-5-6-12-6-4
0000000000000
0000000000000
0000000000000
0000000000000
01210-40005000
0025051374631370
012715974691370
-------------
0000000000000
-3024-10-50-1-20210-5
-2.89-1.75-3.04-11.5-10.5-8.71-8.72-6.98-5.76-6.63-12.35-6.6-4.98
0000000000000

Evoke Pharma stock margins

The Evoke Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Evoke Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Evoke Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Evoke Pharma's sales revenue. A higher gross margin percentage indicates that the Evoke Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Evoke Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Evoke Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Evoke Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Evoke Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Evoke Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Evoke Pharma Margin History

Evoke Pharma Gross marginEvoke Pharma Profit marginEvoke Pharma EBIT marginEvoke Pharma Profit margin
2026e96.1 %35.39 %4.24 %
2025e96.1 %7.6 %0.88 %
2024e96.1 %-37.06 %-15.52 %
202396.1 %-143.44 %-150.41 %
202285.26 %-310.36 %-327.49 %
202179.63 %-503.09 %-527.16 %
2020-300 %-65,250 %-65,750 %
201996.1 %0 %0 %
201896.1 %0 %0 %
201796.1 %0 %0 %
201696.1 %0 %0 %
201596.1 %0 %0 %
201496.1 %0 %0 %
201396.1 %0 %0 %
201296.1 %0 %0 %
201196.1 %0 %0 %

Evoke Pharma Stock Sales Revenue, EBIT, Earnings per Share

The Evoke Pharma earnings per share therefore indicates how much revenue Evoke Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Evoke Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Evoke Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Evoke Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Evoke Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Evoke Pharma Revenue, EBIT and net profit per share

DateEvoke Pharma Sales per ShareEvoke Pharma EBIT per shareEvoke Pharma Earnings per Share
2026e44.75 undefined0 undefined1.9 undefined
2025e27.94 undefined0 undefined0.24 undefined
2024e15.9 undefined0 undefined-2.47 undefined
202318.6 undefined-26.67 undefined-27.97 undefined
20220.8 undefined-2.48 undefined-2.62 undefined
20210.6 undefined-3.04 undefined-3.19 undefined
20200.01 undefined-6.16 undefined-6.2 undefined
20190 undefined-3.84 undefined-3.83 undefined
20180 undefined-5.8 undefined-5.49 undefined
20170 undefined-9.06 undefined-9.86 undefined
20160 undefined-13.51 undefined-13.78 undefined
20150 undefined-21.89 undefined-22.44 undefined
20140 undefined-26.3 undefined-26.5 undefined
20130 undefined-13 undefined-14.2 undefined
20120 undefined-22.22 undefined-22.44 undefined
20110 undefined-26.78 undefined-26.67 undefined

Evoke Pharma business model

Evoke Pharma Inc. is a pharmaceutical company that was founded in 2007 and is based in San Diego, California. It focuses on developing innovative drugs for gastrointestinal disorders. Evoke Pharma is one of the most popular companies on Eulerpool.com.

Evoke Pharma SWOT Analysis

Strengths

Evoke Pharma Inc possesses several strengths that contribute to its competitive advantage in the pharmaceutical industry:

Evoke Pharma Inc offers a unique product that differentiates it from competitors, providing a strong market position.

The company has a dedicated research and development team that continuously works on developing innovative pharmaceutical solutions, enhancing its product pipeline.

Evoke Pharma Inc has established reliable and efficient distribution channels, ensuring its products reach target markets in a timely manner, contributing to increased sales and customer satisfaction.

Weaknesses

Despite its strengths, Evoke Pharma Inc also faces certain weaknesses that it should address to remain competitive:

The company's current product portfolio is relatively limited, which restricts its ability to cater to a diverse range of customer needs and preferences.

Evoke Pharma Inc heavily relies on a few key customers for a significant portion of its revenue, making it vulnerable to changes in their purchasing habits or business decisions.

The company's operations are primarily focused on specific geographical areas, limiting its exposure to potential international markets and growth opportunities.

Opportunities

Evoke Pharma Inc can leverage various opportunities to expand its market presence and drive growth:

The company can explore untapped emerging markets, where demand for pharmaceutical products is increasing due to improving healthcare infrastructure and rising disposable incomes.

Evoke Pharma Inc can establish strategic partnerships with other pharmaceutical companies to gain access to their distribution networks, expand product offerings, and enhance market reach.

By diversifying its product range, Evoke Pharma Inc can cater to a broader customer base, increase market share, and enhance revenue streams.

Threats

Evoke Pharma Inc should also be mindful of potential threats that could negatively impact its business:

The pharmaceutical industry is highly competitive, with numerous established players and new entrants. Evoke Pharma Inc must continuously innovate to differentiate itself from competitors.

Changes in regulations and policies governing the pharmaceutical industry could affect Evoke Pharma Inc's ability to develop, market, and sell its products.

Economic uncertainties, such as fluctuations in currency exchange rates, inflation, or a global recession, could impact consumer purchasing power and reduce demand for Evoke Pharma Inc's products.

Evoke Pharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Evoke Pharma historical P/E ratio, EBIT multiple, and P/S ratio

Evoke Pharma shares outstanding

The number of shares was Evoke Pharma in 2023 — This indicates how many shares 278,580 is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Evoke Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Evoke Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Evoke Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Evoke Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Evoke Pharma stock splits

In Evoke Pharma's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Evoke Pharma.

Evoke Pharma latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.73 -0.93  (-26.63 %)2024 Q2
3/31/2024-2.57 -2.04  (20.63 %)2024 Q1
12/31/2023-6.12 -7.08  (-15.69 %)2023 Q4
9/30/2023-0.63 -0.51  (19.35 %)2023 Q3
6/30/2023-0.74 -0.56  (24.79 %)2023 Q2
3/31/2023-0.59 -0.67  (-13.25 %)2023 Q1
12/31/2022-0.54 -0.53  (1.96 %)2022 Q4
9/30/2022-0.67 -0.6  (10.87 %)2022 Q3
6/30/2022-0.61 -0.71  (-16.01 %)2022 Q2
3/31/2022-0.49 -0.84  (-71.57 %)2022 Q1
1
2
3
4
...
5

Evoke Pharma shareholders

%
Name
Stocks
Change
Date
92.46575 % Nantahala Capital Management, LLC675,000675,0003/25/2024
4.08918 % The Vanguard Group, Inc.29,851012/31/2023
3.87863 % Gonyer (David A)28,31403/25/2024
3.83096 % Garner (Cam L)27,96603/25/2024
3.70753 % Geode Capital Management, L.L.C.27,065012/31/2023
2.71685 % D'Onofrio (Matthew J)19,83303/25/2024
113.01370 % Altium Capital Management LP825,0002,0143/25/2024
113.01370 % Bleichroeder LP825,000825,0002/13/2024
113.01370 % AIGH Capital Management, LLC.825,000825,0002/9/2024
100.72521 % Lytton (Laurence W)735,29403/25/2024
1
2
3
4

Evoke Pharma Executives and Management Board

Mr. David Gonyer59
Evoke Pharma Chief Executive Officer, Co-Founder, Director (since 2007)
Compensation 885,022
Mr. Matthew D'Onofrio53
Evoke Pharma President, Chief Operating Officer, Treasurer, Secretary
Compensation 601,960
Dr. Marilyn Carlson75
Evoke Pharma Chief Medical Officer
Compensation 562,988
Mr. Cam Garner74
Evoke Pharma Independent Chairman of the Board (since 2007)
Compensation 107,040
Ms. Vickie Reed61
Evoke Pharma Independent Director
Compensation 89,249
1
2

Evoke Pharma Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Thermo Fisher Scientific Stock
Thermo Fisher Scientific
SupplierCustomer0,040,30-0,040,32-0,22-0,76
1

Most common questions regarding Evoke Pharma

What values and corporate philosophy does Evoke Pharma represent?

Evoke Pharma Inc represents strong values and embraces a corporate philosophy focused on innovation, patient care, and delivering breakthrough solutions in the pharmaceutical industry. With a steadfast commitment to research and development, Evoke Pharma strives to develop novel therapies that address unmet medical needs. By prioritizing collaboration and maintaining high ethical standards, the company aims to provide patients with effective treatment options. Evoke Pharma Inc consistently seeks to improve healthcare outcomes, enhance patient experiences, and create long-term value for shareholders.

In which countries and regions is Evoke Pharma primarily present?

Evoke Pharma Inc is primarily present in the United States.

What significant milestones has the company Evoke Pharma achieved?

Evoke Pharma Inc has achieved significant milestones. This pharmaceutical company specializes in developing innovative therapies for gastrointestinal disorders. Some of their notable accomplishments include the successful FDA approval of their product EVK-001, a nasal spray for the treatment of diabetic gastroparesis. Additionally, they have forged strategic partnerships with leading healthcare organizations to advance research and development efforts. Evoke Pharma Inc continues to make strides in improving patient care and addressing unmet medical needs in the field of gastrointestinal disorders.

What is the history and background of the company Evoke Pharma?

Evoke Pharma Inc is a pharmaceutical company that specializes in developing innovative therapies for gastrointestinal disorders. Founded in 2007, the company is based in San Diego, California. Evoke Pharma is dedicated to improving patient outcomes by addressing unmet medical needs through its proprietary delivery technologies. With a strong focus on developing treatments for diabetic gastroparesis, a condition characterized by delayed gastric emptying, Evoke Pharma aims to provide effective solutions for patients worldwide. The company has made significant strides in advancing its product pipeline and collaborating with key partners to bring these much-needed therapies to the market.

Who are the main competitors of Evoke Pharma in the market?

The main competitors of Evoke Pharma Inc in the market include companies such as Johnson & Johnson, Pfizer, Novartis, GlaxoSmithKline, and AstraZeneca.

In which industries is Evoke Pharma primarily active?

Evoke Pharma Inc is primarily active in the pharmaceutical industry.

What is the business model of Evoke Pharma?

The business model of Evoke Pharma Inc is focused on developing and commercializing innovative therapies for gastrointestinal diseases. The company primarily focuses on the development of EVK-001, a patented nasal spray formulation of metoclopramide, which is intended to treat symptoms associated with diabetic gastroparesis. Evoke Pharma Inc aims to provide a safe and effective treatment option to patients suffering from this condition. By leveraging its expertise in drug development and commercialization, Evoke Pharma Inc endeavors to improve the quality of life for individuals with gastrointestinal disorders.

What is the P/E ratio of Evoke Pharma 2024?

The Evoke Pharma P/E ratio is -0.83.

What is the P/S ratio of Evoke Pharma 2024?

The Evoke Pharma P/S ratio is 0.13.

What is the Quality Investing of Evoke Pharma?

The Quality Investing for Evoke Pharma is 6/10.

What is the revenue of Evoke Pharma 2024?

The expected Evoke Pharma revenue is 11.61 M USD.

How high is the profit of Evoke Pharma 2024?

The expected Evoke Pharma profit is -1.8 M USD.

What is the business model of Evoke Pharma

Evoke Pharma Inc is a biopharmaceutical company focused on developing innovative solutions for unmet medical needs. The company specializes in the development and marketing of therapeutics to improve the lives of patients. The company has two main divisions: product development and marketing. The emphasis of product development is on developing new drugs, with a focus on gastrointestinal (GI) diseases. The company's goal is to create products that are more effective than current market offerings. One of the company's key products is Gimoti, which is used to treat nausea and vomiting in adults with gastroparesis. Gimoti is a dopamine receptor antagonist and the first oral spray approved by the FDA for gastroparesis treatment. Evoke Pharma Inc aims to strengthen the market position and awareness of Gimoti while expanding its product portfolio. The company collaborates with the FDA to explore additional uses for Gimoti and meet more medical needs. Evoke Pharma Inc follows an innovative business model, emphasizing collaboration with leading medical institutions and experts in the field of GI diseases. The company conducts extensive research and development to expand its product pipeline and strengthen its market position. It also employs a comprehensive marketing strategy, utilizing social media as an important sales channel to provide relevant and timely information to its target audience. Overall, Evoke Pharma Inc offers an innovative approach to the development and marketing of products for GI diseases. The company has released Gimoti, a promising product, and is expected to launch more products in the near future to improve the lives of patients with unmet medical needs.

What is the Evoke Pharma dividend?

Evoke Pharma pays a dividend of 0 USD distributed over payouts per year.

How often does Evoke Pharma pay dividends?

The dividend cannot currently be calculated for Evoke Pharma or the company does not pay out a dividend.

What is the Evoke Pharma ISIN?

The ISIN of Evoke Pharma is US30049G1040.

What is the Evoke Pharma WKN?

The WKN of Evoke Pharma is A1W6DP.

What is the Evoke Pharma ticker?

The ticker of Evoke Pharma is EVOK.

How much dividend does Evoke Pharma pay?

Over the past 12 months, Evoke Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Evoke Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Evoke Pharma?

The current dividend yield of Evoke Pharma is .

When does Evoke Pharma pay dividends?

Evoke Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Evoke Pharma?

Evoke Pharma paid dividends every year for the past 0 years.

What is the dividend of Evoke Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Evoke Pharma located?

Evoke Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Evoke Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Evoke Pharma from 10/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/18/2024.

When did Evoke Pharma pay the last dividend?

The last dividend was paid out on 10/18/2024.

What was the dividend of Evoke Pharma in the year 2023?

In the year 2023, Evoke Pharma distributed 0 USD as dividends.

In which currency does Evoke Pharma pay out the dividend?

The dividends of Evoke Pharma are distributed in USD.

All fundamentals about Evoke Pharma

Our stock analysis for Evoke Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Evoke Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.